February 12, 2022

The National Stock Exchange of India Ltd. BSE Limited

Listing Department Department of Corporate Services
Exchange Plaza, Floor 25, Phiroze Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (East), Dalal Street,
Mumbai - 400 051 Mumbai – 400 001

Company Symbol: DHARAMSI Scrip Code : 506405

Sub: Investor Presentation for Q3FY22.

Dear Sir/Madam,

Pursuant to Regulation 30(6) of the SEBI (Listing Obligation and Disclosure Requirements)
Regulation 2015, we are enclosing herewith Investor Presentation on the Company’s Financial
Performance of Q3FY22.

The said presentation will also be made available at the website of the Company at
https://www.dmcc.com→Investor→Announcements→Analyst-Investor-Meets→Investor
Presentations

You are requested to kindly take the same on your record.

Thanking you,

For The Dharamsi Morarji Chemical Company Limited

OMKAR Digitally signed by OMKAR
CHANDRAKANT MHAMUNKAR
CHANDRAKANT Date: 2022.02.12 15:58:07
MHAMUNKAR +05'30'

Omkar Mhamunkar
Company Secretary & Compliance Officer
ICSI Membership No. ACS 26645

Encl : As Above

CIN NUMBER: L24110MH1919PLC000564

Regd. Office : PROSPECT CHAMBERS, 317/21, DR. D.N. ROAD, FORT, MUMBAI – 400 001. INDIA
Tel : 2204 8881-2-3 | Fax : 2285 2232 | E-mail ID : investor@dmcc.com | Website : www.dmcc.com
Q3FY22 EARNINGS PRESENTATION
(FEBRUARY 2022)
Safe This investor presentation has been prepared by The Dharamsi Morarji Chemicals Company Limited (“DMCC”) and
does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This
presentation or any other documentation or information (or any part thereof) delivered or supplied should not be
Harbour deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance
should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions
contained herein. The information contained in this presentation is only current as of its date. Certain statements
made in this presentation may not be based on historical information or facts and may be “forward looking
statements”, including those relating to the general business plans and strategy of DMCC, its future financial
condition and growth prospects, future developments in its industry and its competitive and regulatory
environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’,
‘strong growth prospects’, etc., or similar expressions or variations of such expressions. These forward-looking
statements involve a number of risks, uncertainties and other factors that could cause actual results,
opportunities and growth potential to differ materially from those suggested by the forward-looking statements.
These risks and uncertainties include, but are not limited to risks with respect to its hair care, its healthcare
business and its skin care business. DMCC may alter, modify or otherwise change in any manner the content of this
presentation, without obligation to notify any person of such revision or changes. This presentation cannot be
copied and disseminated in any manner.
QUARTERLY UPDATES To view our corporate film
Visit: https://bit.ly/3ePHS7S
M ANAGE M E NT R E M AR K S
or Scan the QR code.

U PDATE S O N C APE X

C O NTAC T U S
 Y-o-Y Q-o-Q
Financial Statement Summary
(Q3 FY22 vs Q3 FY21) (Q3 FY22 vs Q2 FY22)

72.19% 12.34%
Q3FY22 Revenue from Q3FY22 Revenue from
Figures in INR Crores
Operations at INR 81.48 Operations at INR
crores as compared to 81.48 crores as
INR 47.32 crores in compared to INR 72.53
PARTICULARS Q3FY22 Q2FY22 Q3FY21 9MFY22 9MFY21 Q3FY21 crores in Q2FY22

Revenue from Operations 81.48 72.53 47.32 224.66 136.26

30.91% 47.40%
Total Income 81.74 73.39 48.22 227.59 143.64 Q3FY22 EBITDA at INR Q3FY22 EBITDA at INR
11.69 crores as 11.69 crores as
Total Operating Expense 70.05 65.46 39.29 195.17 111.15 compared to INR 8.93 compared to INR 7.93
crores in Q3FY21 crores in Q2FY22

EBITDA 11.69 7.93 8.93 32.42 32.49

41.98% 67.53%
EBITDA Margins % 14.35% 10.93% 18.87% 14.43% 23.84% Q3FY22 PBT at INR Q3FY22 PBT at INR
9.03 crores as 9.03 crores as
Interest Cost 0.83 0.73 0.87 2.05 2.03 compared to INR 6.36 compared to INR 5.39
crores in Q3FY21 crores in Q2FY22

Depreciation and Amortisation 1.83 1.81 1.70 5.43 5.07

36.44% 75.96%
Profit Before Taxes 9.03 5.39 6.36 24.94 25.39* Q3FY22 Profit After Tax Q3FY22 Profit After Tax
at INR 6.44 crores as at INR 6.44 crores as
compared to INR 4.72 compared to INR 3.66
Profit After Taxes 6.44 3.66 4.72 17.62 21.82
crores in Q3FY21 crores in Q2FY22.

CLICK HERE to view the financial results - https://www.bseindia.com/xml-data/corpfiling/AttachLive/4e1eff1c-39f6- * 9M FY21 PBT includes one time profit of
4952-9c8d-945b4d61b016.pdf 4.94 crores from sale of closed Khemli unit.
Management Remarks
FINANCIAL PERFORMANCE: SEGMENT PERFORMANCE: OPERATING ENVIRONMENT: CORPORATE ACTIONS:
• The Company recorded a strong growth in • Despite a difficult operating environment, the company • The prices of raw materials have continued • The Company successfully
revenues in Q3FY22 as the revenues increased delivered a strong performance in the specialty to rise. While the Company has been listed its equity shares on the
by 72.19% to INR 81.48 crores as against INR successful in passing on increases in input National Stock Exchange of
chemicals segment. In comparison to Q2FY22, the
47.32 crores in Q3FY21. The growth in prices for specialty chemicals, higher input India Limited (NSE) on 1st
revenues is attributable to higher realisations Company successfully passed on increased input costs costs for bulk chemicals continue to Decemeber 2021.
and moderate increase in volumes. in Q3FY22. remain a challenge.
• EBITDA came in at INR 11.69 crores as against • Adding on to the existing raw material availability • The freight and logistics cost continue to
INR 8.93 crores in Q3FY21 recording a growth issues, the Company encountered additional raw escalate. The Company will continue to
of 30.91% on a Y-o-Y basis. The EBITDA pass them on to the customers.
material shortages as a result of a force majeure event
margins came in at 14.35% as against 18.87%
in Q3FY21 mainly on account of higher raw at the vendor's facility.
• With the commercialization of the bulk
material prices. • For bulk chemicals, Q3FY22 was a mixed bag, as higher chemicals plant in Dahej and the
• A strong growth in top line aided the realisations continued to drive top line growth, but the upcoming phased expansions in specialty
profitability, which came in at INR 6.44 crores increase in raw materials costs could not be passed on chemicals, the Company is well positioned
in Q3FY22 as against INR 4.72 crores in Q3FY21. to deliver a strong performance in the
completely, reducing overall profitability. times to come.

PARTICULARS Q3 FY22 Q2 FY22

PARTICULARS Q3 FY22

Ex p o rt sal e s 28% 32% Sale of specialty chemicals including exports ~55%

Do m e st ic sal e s 72% 68% Sale of bulk chemicals ~45%

Update on Capex
Debottlenecking at Roha Multipurpose plants at Bulk chemicals at Dahej Specialty chemicals at Intermediates Plant at
Dahej Dahej Dahej

The company has invested ~ INR 10 The company has invested ~ INR 10 The company will be investing INR The company will invest The company will invest INR 20
crores on this project. crores in 2 multipurpose plants at 50 crores in adding incremental INR 20 Crores in a dedicated plant at crores for expansion to manufacture
the Dahej facility. capacity in bulk chemicals segment. Dahej facility. intermediates for pharmaceutical
and agrochemical industry.

Complete Complete Complete The plant is expected to begin This project is expected to complete
commercial production by Q4FY22 by Q1FY23

Commercial production has started The Commercial production has The Commercial production has The company will use this facility for The company had earlier decided to
and the volumes are expected to started and the volumes are started and we expect to ramp up manufacturing products under invest this amount in Sulfones.
further ramp up in Q4FY22 expected to further ramp up in the production to optimum contract. The products to be However with a downturn in the
Q4FY22 utilisations by the end of Q1FY23 manufactured and other details international markets for the
remain confidential as the company product category, the plan has been
has signed an NDA. put on hold
Get in
Touch

MR. OMKAR MHAMUNKAR MR. ABHISHEK MEHRA

Company Secretary and Compliance Investor Relations Advsior

Officer
The Investment Lab
The Dharamsi Morarji Chemical Co.
Limited abhishek@theinvestmentlab.in

omhamunkar@dmcc.com